Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer
American Society of Clinical Oncology Educational Book · 2024
DOI: 10.1200/edbk_432500 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024. Verfasst von Jamie E Chaft und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Clinical investigation of immune checkpoint inhibitors (ICIs) has expanded from indications in metastatic non–small cell lung cancer (NSCLC) to add to the treatment of early-stage or resectable NSCLC. Although completed randomized trials supported the approvals of some ICIs as perioperative therapies (ie, adjuvant, neoadjuvant, or neoadjuvant followed by adjuvant), ongoing trials are evaluating other anti–PD-(L)1 antibodies for similar indications, or in combination with stereotactic body radiotherapy (SBRT). The incorporation of immunotherapy brings potential to improve outcomes of patients with resectable NSCLC, but these advances have also increased the complexity of the treatment landscape and created important knowledge gaps. This article reviews the current standards for local therapies in NSCLC, describes the clinical trials exploring the combination of ICIs to SBRT, and explains the recent approvals of ICIs as perioperative therapies. A discussion follows to highlight three important areas of uncertainty: (1) the contribution of ICIs given in each treatment phase (neoadjuvant and adjuvant) to the overall effect of neoadjuvant chemoimmunotherapy followed by adjuvant ICIs; (2) the selection of regimens to serve as comparators in future randomized trials of perioperative therapies; and (3) the role of pathologic complete response as an intermediate end point and aid for selection of patients for adjuvant therapy. Moving forward, stakeholders will need to engage in concerted research efforts to address the relevant clinical questions regarding the optimal management of resectable NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Dept. of Oncology and Radiotherapy and Early Phase Clinical Trials Center, Medical University of Gdansk, Gdańsk, Poland.
- Office of Oncologic Diseases, US Food and Drug Administration, Silver Spring, MD.
ORCID-Profile: Jamie E Chaft, Rafal Dziadziuszko, Bernardo Haddock Lobo Goulart
Zitieren
APA
Chaft, J. E., Dziadziuszko, R., & Haddock Lobo Goulart, B. (2024). Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_432500
Vancouver
Chaft JE, Dziadziuszko R, Haddock Lobo Goulart B. Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book. 2024. doi:10.1200/edbk_432500
BibTeX
@article{Chaft2024,
author = {Chaft, Jamie E and Dziadziuszko, Rafal and Haddock Lobo Goulart, Bernardo},
title = {Moving Immunotherapy Into the Treatment of Resectable Non–Small Cell Lung Cancer},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
doi = {10.1200/edbk_432500}
}
EUVIMED